Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Aptevo Therapeutics Inc
APVO
Healthcare
Biotechnology
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on developing novel immunotherapy candidates for the treatment of different forms of cancer. It has developed two versatile and enabling platform technologies for rational design of precision immune modulatory drugs. Its lead clinical candidates, APVO436 and ALG.APV-527, and preclinical candidates, APVO603 and...
APVO711, are developed using its ADAPTIR modular protein technology platform. Its preclinical candidate APVO442 is developed using its ADAPTIR-FLEX modular protein technology platform. APVO436 is a bispecific ADAPTIR that is designed to engage CD3 and CD123 to redirect T-cells to destroy leukemia cells expressing the target CD123 molecule on their surface. ALG.APV-527 is a novel investigational bispecific ADAPTIR candidate. APVO603 is a preclinical dual agonist bispecific ADAPTIR candidate designed to simultaneously target 4-1BB (CD137) and OX40 (CD134), both members of the TNF-receptor family.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:APVO)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
Next
(229)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Jul 17, 2024 1:47pm
Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 3
News; $APVO Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session | BenzingaShares of ASLAN Pharmaceuticals Limited (NASDAQ
...more
(79)
•••
coolfooldumbguy
X
View Profile
View Bullboard History
Post by
coolfooldumbguy
on Jul 17, 2024 10:41am
Using technical analysis for this one.
Big buy for me at .46 cents per share,so glta and do your own due diligence,but the worst seems to be over for this company and its stock.
Level Up Your Trading with BMO InvestorLine’s Enhanced Features
posted Nov 24, 2024 9:00am by
Bank of Montreal
-
|
Features like Multi-Leg Orders, Options Screener, and Strategy Builder will be particularly exciting for traders. They have been designed to be intuitive and user-friendly, regardless of your experience level. Whether you’re a seasoned pro or just starting out, you’ll find these tools easy to navigate and adapt to your investing style. ...read more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on May 14, 2024 8:06am
New Press Release - Aptevo Therapeutics Presenting at The Protein & Antibody Engineering Summit, Boston, MA
Lecture to focus on engineering strategies applied to design safe and efficacious bispecific drug candidates, utilizing our proprietary platform technologiesSEATTLE, WA / ACCESSWIRE / May 14, 2024/ Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on May 08, 2024 8:07am
New Press Release - Aptevo Therapeutics Reports 1Q 2024 Financial Results and Provides a Business Update
Heavily pre-treated breast cancer patient who achieved stable disease on study, remains on treatment for more than eleven months after entering the ALG.APV-527 Phase 1 trial with progressive disease and transitioning to higher dose with potential for greater clinical benefit, experienced no new...
read article.
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on May 02, 2024 9:37am
APVO......sold all this a.m into strength
Cha -Ching!!!!!!!
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Apr 15, 2024 4:13pm
New Press Release - Aptevo Therapeutics Announces Closing of $4.6 Million Public Offering
SEATTLE, WA / ACCESSWIRE / April 15, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced the closing of its...
read article.
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Apr 15, 2024 10:44am
APVO.....come on down!!!!!!!!!!!
Let this drop like a rock ; )
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Apr 15, 2024 10:29am
APVO....N.L.O.D.....LoL
Sub 70 ? Probably
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Comment by
Iseneschal
on Apr 12, 2024 11:05am
RE:Why Aptevo Therapeutics Stock Is Cratering | Benzinga
I'd say The Maggot has to change the way he does RS's......people start to catch on to the way Mr. M works. Surprise the masses...whodda thunk that the Powers to Be would do a financing that
...more
(229)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Apr 11, 2024 5:15pm
Why Aptevo Therapeutics Stock Is Cratering | Benzinga
News; $APVO Why Aptevo Therapeutics Stock Is Cratering | BenzingaAptevo Therapeutics Inc. (NASDAQ:APVO) shares are trading lower Thursday after the company priced its $4.6 million public offering.The
...more
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Apr 11, 2024 10:19am
APVO....big meltdownsince my last post....
I knew that there was to be a financing sooner or later....just didn't figure on a P.O at $1.35 I'd call that $ raise exercise .... "A Curveball" Let's see what happens
...more
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Apr 10, 2024 9:09am
APVO....NR this a.m
Aptevo Therapeutics Provides Pipeline Update 2024-04-10 06:04 ET - News Release Breast cancer patient who improved from a progressive disease diagnosis to an over nine-month sustained
...more
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Apr 05, 2024 2:52pm
APVO....PoP....WTF?
missed it
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Mar 18, 2024 6:01am
New Press Release - Aptevo Participating in The Springtime Partnering Event, a Bio-Europe Conference
SEATTLE, WA / ACCESSWIRE / March 18, 2024/ Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced that the Company is...
read article.
(229)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Mar 07, 2024 2:00pm
Why Is Immuno-Oncology Focused Aptevo Therapeutics Stock Tra
Just In: $APVO Why Is Immuno-Oncology Focused Aptevo Therapeutics Stock Trading Higher On Thursday? | BenzingaThursday,@Alligator Bioscience AB@and@Aptevo Therapeutics Inc@(NASDAQ:APVO) released
...more
Prev
1
2
3
4
5
6
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >